Back to Journals » ImmunoTargets and Therapy » Volume 2

Update on the challenges and recent advances in cancer immunotherapy

Authors Baronzio G, Parmar G, Shubina I, Cassutti V, Giuli S, Ballerini M, Kiselevsky M

Received 16 January 2013

Accepted for publication 19 March 2013

Published 17 June 2013 Volume 2013:2 Pages 39—49

DOI https://doi.org/10.2147/ITT.S30818

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4


Gianfranco Baronzio,1 Gurdev Parmar,2 Irina ZH Shubina,3 Valter Cassutti,1 Sergio Giuli,1 Marco Ballerini,1 Mikhail Kiselevsky3

1Centro Medico Demetra: Hyperthermia and Immunity Center, Terni, Italy; 2Integrated Health Clinic, Fort Langley, British Columbia, Canada; 3Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia

Abstract: This overview provides an analysis of some of the immunotherapies currently in use and under investigation, with a special focus on the tumor microenvironment, which we believe is a major factor responsible for the general failure of immunotherapy to date. It is our expectation that combining immunotherapy with methods of altering the tumor microenvironment and targeting regulatory T cells and myeloid cells will yield favorable results.

Keywords: tumor microenvironment, tumor immunity, immunosuppression, CTLA-4, PD-1, exosomes, myeloid-derived suppressor cells, Tregs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]